Saeve

https://www.kaziatherapeutics.com › site › for-researchers › paxalisib
Kazia is an Australian oncology company developing innovative high impact drugs for cancer Our lead program is paxalisib which is being developed to treat glioblastoma the most common and most

https://www.prnewswire.com › news-releases
SYDNEY May 26 2026 PRNewswire Kazia Therapeutics Limited NASDAQ KZIA Kazia or the Company a clinical stage oncology company advancing therapies designed to reprogram cancer

https://www.plataformamedia.com › en › kazia-therapeutics...
We remain encouraged by the safety and tolerability data observed to date and expanding enrollment allows us to generate a broader clinical and translational dataset as we

https://www.advfn.com › stock-market › NASDAQ › KZIA › stock-news › ...
GBM AGILE trial data shows clinically meaningful improvement in a prespecified secondary analysis for overall survival in paxalisib treated newly diagnosed unmethylated patients with

https://www.ajmc.com › view › kazia-therapeutics-discusses-shift-for...
Kazia Therapeutics advances paxalisib a dual PI3K mTOR inhibitor into triple negative breast cancer boosting immunotherapy responses with early promising data

https://www.marketbeat.com › stocks › NASDAQ › KZIA › fda-events
Novogen s Drug in the FDA Approval Process This section highlights FDA related milestones and regulatory updates for drugs developed by Novogen KZIA Over the past two years

https://www.prnewswire.com › news-releases › kazia-therapeutics-reports...
After nine cycles of therapy serial imaging demonstrated continued tumor reduction at each assessment culminating in a partial response by iRECIST criteria The patient remains active

https://seekingalpha.com › symbol › KZIA › press-releases
Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer PR NewswireThu Jan 30

https://www.tipranks.com › news › company-announcements
Kazia Therapeutics Limited is a Sydney based clinical stage oncology drug developer focused on therapies that reprogram cancer biology and overcome treatment resistance